Enloplatin

This classification denotes a platinum compound with the molecular formula C7H16N2O.C6H6O4.Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7HT2IO79H, chemically known as platinum, (1,1-cyclobutanedicarboxylato(2-))(tetrahydro-4h-pyran-4,4-dimethanamine-n,n)-, (sp-4-2)- but more generally known as enloplatin, which bears US NIH Compound Identifier 68737. European Medicines Agency schedules Enloplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06536MIG. The term ENLOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Enoplatin bears NCI CUID C95323 and UMLS ID C0165431. ENLOPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cisplatin under HS 28439000 and SITC 52432. SMILES: C1CC(C1)(C(=O)[O-])C(=O)[O-].C1COCCC1(CN)CN.[Pt+2].